What is HC Wainwright’s Forecast for AMLX FY2029 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Investment analysts at HC Wainwright raised their FY2029 earnings per share (EPS) estimates for shares of Amylyx Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 10th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of $0.80 for the year, up from their previous estimate of $0.21. HC Wainwright currently has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2030 earnings at $2.29 EPS.

AMLX has been the subject of a number of other reports. Robert W. Baird raised their price target on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Citigroup raised their target price on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Lifesci Capital upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 27th. Finally, Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Amylyx Pharmaceuticals Stock Down 2.0%

AMLX opened at $14.07 on Thursday. The firm has a market capitalization of $1.55 billion, a P/E ratio of -7.82 and a beta of -0.31. The firm’s 50 day moving average is $13.39 and its 200-day moving average is $12.51. Amylyx Pharmaceuticals has a 52-week low of $2.60 and a 52-week high of $17.49.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. MetLife Investment Management LLC lifted its holdings in Amylyx Pharmaceuticals by 15.7% during the 4th quarter. MetLife Investment Management LLC now owns 49,654 shares of the company’s stock valued at $600,000 after purchasing an additional 6,725 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Amylyx Pharmaceuticals by 867.3% in the fourth quarter. Renaissance Technologies LLC now owns 192,500 shares of the company’s stock valued at $2,325,000 after buying an additional 172,600 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Amylyx Pharmaceuticals by 51.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 771,248 shares of the company’s stock valued at $9,316,000 after buying an additional 261,468 shares in the last quarter. Integrated Quantitative Investments LLC bought a new position in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $329,000. Finally, Federated Hermes Inc. lifted its position in Amylyx Pharmaceuticals by 115.4% during the 4th quarter. Federated Hermes Inc. now owns 457,412 shares of the company’s stock worth $5,526,000 after buying an additional 245,033 shares in the last quarter. 95.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Justin B. Klee sold 1,995 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $13.89, for a total value of $27,710.55. Following the completion of the transaction, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at $46,939,838.22. This represents a 0.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Karen Firestone bought 8,100 shares of the stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average price of $12.45 per share, for a total transaction of $100,845.00. Following the purchase, the director directly owned 63,100 shares of the company’s stock, valued at approximately $785,595. This represents a 14.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 157,783 shares of company stock worth $2,122,808. 12.30% of the stock is owned by company insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.